Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TMPRSS15 | P98073 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 2/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099173 | 0.95 | TSHR (0.48) | TSHRNOS3NOS1NOS2MEN1 | |
| SCHEMBL4098732 | 0.93 | TSHR (0.47) | TSHRNOS3NOS1NOS2MEN1 | |
| SCHEMBL4097713 | 0.89 | KMT2A (0.55) | TSHRNOS3NOS1NOS2MEN1 | |
| SCHEMBL4093126 | 0.82 | CYP1A2 (0.52) | TSHRNOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL4111862 | 0.81 | NOS3 (0.49) | TSHRNOS3NOS1NOS2MEN1 | |
| SCHEMBL4104470 | 0.80 | DNM1 (0.49) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL4099423 | 0.79 | NOS3 (0.58) | TSHRNOS3NOS1NOS2KMT2A | |
| SCHEMBL4100364 | 0.77 | CYP1A2 (0.50) | TSHRNOS3NOS1NOS2KMT2A | |
| SCHEMBL3056410 | 0.76 | CA1 (0.41) | TSHRNOS3NOS1NOS2MEN1 | |
| SCHEMBL4100420 | 0.76 | CYP1A2 (0.49) | TSHRNOS3NOS1NOS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090194124-A1 | Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine | MALLE GERARD | 2009-08-06 | — | — | US | disclosed |
| US-20090139537-A1 | HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE | L'OREAL S.A. | 2009-06-04 | — | — | US | disclosed |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | L'OREAL S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | L'OREAL | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139537-A1 | HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE | KRT18, INMT, INHA | TSHR 1694/4885NOS3 323/4885NOS1 166/4885 |
| US-20090194124-A1 | Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine | KRT18, KIT, PRDM7 | TSHR 3766/4885NOS3 1293/4885NOS1 591/4885 |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | KRT18, INHA, H1-5 | TSHR 3770/4885NOS3 1322/4885NOS1 681/4885 |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | BHMT, KRT18, INMT | TSHR 1691/4885NOS3 634/4885NOS1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.